| Online-Ressource |
Verfasst von: | Jaramillo Segura, Sonia [VerfasserIn]  |
| Benner, Axel [VerfasserIn]  |
| Schlenk, Richard Friedrich [VerfasserIn]  |
Titel: | Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia |
Verf.angabe: | S. Jaramillo, A. Benner, J. Krauter, H. Martin, T. Kindler, M. Bentz, H. R. Salih, G. Held, C.-H. Köhne, K. Götze, M. Lübbert, A. Kündgen, P. Brossart, M. Wattad, H. Salwender, B. Hertenstein, D. Nachbaur, G. Wulf, H.-A. Horst, H. Kirchen, W. Fiedler, A. Raghavachar, G. Russ, S. Kremers, E. Koller, V. Runde, G. Heil, D. Weber, G. Göhring, K. Döhner, A. Ganser, H. Döhner, R. F. Schlenk |
E-Jahr: | 2017 |
Jahr: | 26 May 2017 |
Umfang: | 8 S. |
Fussnoten: | Published online 26 May 2017 ; Gesehen am 14.08.2018 |
Titel Quelle: | Enthalten in: Blood cancer journal |
Ort Quelle: | London [u.a.] : Nature Publishing Group, 2011 |
Jahr Quelle: | 2017 |
Band/Heft Quelle: | 7(2017,5) Artikel-Nummer e564, 8 Seiten |
ISSN Quelle: | 2044-5385 |
Abstract: | The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival. |
DOI: | doi:10.1038/bcj.2017.45 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Kostenfrei: Volltext ; Verlag ; Resolving-System: https://www.nature.com/articles/bcj201745 |
| Kostenfrei: Volltext: http://dx.doi.org/10.1038/bcj.2017.45 |
| DOI: https://doi.org/10.1038/bcj.2017.45 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1578855837 |
Verknüpfungen: | → Zeitschrift |
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia / Jaramillo Segura, Sonia [VerfasserIn]; 26 May 2017 (Online-Ressource)